This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Frustrating Boston Scientific Is Not What the Investor Ordered

Stocks in this article: BSX MDT ABT JNJ STJ

NEW YORK (TheStreet) – Boston Scientific (BSX - Get Report) continues to frustrate its shareholders. The shares peaked in January at $14.08 and have grossly underperformed its peers ever since.

Yet, the stock at around $12, is up 3% on the year to date.

While that 3% may seem respectable relative to the 3% gain of the Dow Jones Industrial Average, the shares have gotten punished their $14.08 head-fake in January. Investors have seen more than 12% of their wealth erode. During that same span, rivals Medtronic (MDT) and Abbott Labs (ABT) have posted gains of close to 9% each.

Read More: 7 Stocks Warren Buffett Is Selling in 2014

Making matters worse, shares of Boston Scientific, which trade at a price-to-earnings ratio of 45, are still not cheap. That 20 points above the industry aver P/E of 20, according to Yahoo! Finance.

With the medical device company delivering just 4% year-over-year revenue growth compared to, say, Johnson & Johnson (JNJ) , which is growing at 9%, there's still plenty of risk to the downside. Plus investors can buy Johnson & Johnson at a P/E of 20, lower their risk and enjoy a 2.8% yield compared to no dividend for Boston Scientific.

So for all of the reasons investors should jump into St. Jude Medical (STJ) , Boston Scientific should be avoided. With the stock trading around $12, it only takes one bad quarter or unfavorable product study to send these shares down to single digits. Only then will I recommend them as a buy.

Truth be told, I've always wanted to like this company. Its medical devices are used in a range of interventional medical specialties. There's no evidence that Boston Scientific -- although much improved -- has enough firepower to outgrow Medtronic and St. Jude. Both are making significant investments to secure their positions in the devices market.

Read More: Chipotle's Monty Moran Unwraps the Restaurant's Success Story

Now that there are signs that device growth has stabilized, Boston Scientific still lacks the operational leverage to deliver on the bottom line. Its gross margin of 68% trails both Medtronic and St. Jude. And in terms of operating margin, Boston Scientific's 13% is half of not only Medtronic and St. Jude, but also Johnson & Johnson.

So where's the value?

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,416.85 +225.48 1.31%
S&P 500 2,021.25 +19.09 0.95%
NASDAQ 4,683.4070 +45.4130 0.98%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs